Specialized Therapies | HIV and Oncology
Press Releases and Company Announcements
Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2021 and Provides Business Update
Q3 Earnings Call – Participant Q&A via Webcast
Theratechnologies to Present at the H.C. Wainwright 5th Annual Nash Investor Conference
Theratechnologies to Announce Financial Results for Its Third Quarter Fiscal 2021
Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies. We currently have a Phase 1 clinical trial underway in oncology using our novel and proprietary SORT1+ Technology™. We also plan to initiate a Phase 3 clinical trial to evaluate tesamorelin as a potential treatment for NASH, a severe liver condition which affects a growing number of people around the world.
Making a difference through innovation
Theratechnologies makes a difference in the lives of patients through the development and commercialization of products addressing important unmet medical needs.